Oncology

Pharma News for Nkarta, Eisai, EQRx, Rigel Pharma, AUM, X4 Pharma

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, declared that the U.S. FDA has permitted Orphan Drug Designation for AUM302. For the treatment of neuroblastoma, AUM302 is a potential first-in-class oral kinase inhibitor that not only targets PI3K but also important resistance mechanisms like PIM and mTOR. Preclinical studies of AUM302 have showed that complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition can improve clinical outcomes in children having high-risk of neuroblastoma and inhibit canc...

Explore More...

Pharma happenings for Urovant's vibegron Genmab and Polyphor

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Biliary tract cancer market | BTC Market

Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape

recent-pharma-happenings-for-pfizer-sanofi-elevation-oncology

Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M

lung-cancer-symptoms-risk-factors-and-treatment-options

Lung Cancer and its Increasing Global Burden

Albireo's PFIC Therapy; Lupin’s Trichomoniasis Drug; Moderna's COVID vaccine; NASH Cocktail Therapy

Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Against COVID; Gilead & Novo Nordisk’s Cocktail Therapy for NASH

recent-pharma-news-and-updates-for-novartis-gsk-exact-sciences-eqrx

Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone’s deal for checkpoint inhibitors

Pharma news for Bayer, Novartis, Forma, AskBio

Bayer eyes AskBio’s Gene Therapies; Novartis’ Iptacopan; Forma’s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic

NMIBC Market Size | NMIBC Market Drivers and Barriers

Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years

recent-pharma-news-and-updates-for-santhera-merck-novartis-scribe

Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma

Opioid-overdose-addiction-abuse-epidemic-crisis

Brain’s immune cells research update; Moderna’s COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant’s relugolix falls short in metastatic prostate cancer; Alnylam’s lumasiran phase 3 result

Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing

Samsung/AZ Deal; Gyroscope’s GT005; Inflazome's Buyout; Abbott's MitraClip4; Grail Buyback

Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome’s Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks

recent-pharma-happenings-for-eli-lilly-aziyo-biologics-bms

Lilly’s COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian’s CD40L cell therapy

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape

Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M

Lung Cancer and its Increasing Global Burden

Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Against COVID; Gilead & Novo Nordisk’s Cocktail Therapy for NASH

Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone’s deal for checkpoint inhibitors

Bayer eyes AskBio’s Gene Therapies; Novartis’ Iptacopan; Forma’s IDH1-Mutated AML Therapy; EpicGenetics teams up with Mayo Clinic

Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years

More Views & Analysis

Santhera flunks DMD phase 3; Scribe emerges with $20 M; Merck sells off Osteoarthritis drug to Novartis; Research updates on flu vaccine and glioblastoma

How do we curb the Opioid Epidemic?

Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade

Pitfalls of Current Osteosarcoma Treatment Approaches

Brain’s immune cells research update; Moderna’s COVID-19 vaccine; Pfizer funnels $200 M into CStone; Myovant’s relugolix falls short in metastatic prostate cancer; Alnylam’s lumasiran phase 3 result

Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing

Samsung/AZ Deal; Gyroscope’s Dry AMD Gene Therapy; Inflazome’s Buyout; Abbott’s MitraClip4 EU Approval; Grail Buybacks

Lilly’s COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian’s CD40L cell therapy

Subscribe to our Updates

Daily

Weekly

Monthly